BidaskClub cut shares of Rockwell Medical (NASDAQ:RMTI) from a hold rating to a sell rating in a research note published on Friday morning.
Separately, Zacks Investment Research upgraded shares of Rockwell Medical from a hold rating to a buy rating and set a $7.50 target price for the company in a research note on Wednesday, October 25th.
Rockwell Medical (RMTI) opened at $6.09 on Friday. The stock has a market capitalization of $315.22, a PE ratio of -14.16 and a beta of 2.01. Rockwell Medical has a twelve month low of $5.06 and a twelve month high of $8.98.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Teachers Advisors LLC boosted its stake in shares of Rockwell Medical by 1.5% during the second quarter. Teachers Advisors LLC now owns 88,772 shares of the company’s stock worth $704,000 after buying an additional 1,335 shares during the period. TIAA CREF Investment Management LLC boosted its stake in shares of Rockwell Medical by 1.1% during the second quarter. TIAA CREF Investment Management LLC now owns 132,131 shares of the company’s stock worth $1,048,000 after buying an additional 1,401 shares during the period. Cutter & CO Brokerage Inc. boosted its stake in shares of Rockwell Medical by 6.3% during the second quarter. Cutter & CO Brokerage Inc. now owns 25,325 shares of the company’s stock worth $201,000 after buying an additional 1,500 shares during the period. Voya Investment Management LLC boosted its stake in shares of Rockwell Medical by 11.9% during the second quarter. Voya Investment Management LLC now owns 27,232 shares of the company’s stock worth $216,000 after buying an additional 2,895 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of Rockwell Medical by 11.3% during the first quarter. Metropolitan Life Insurance Co. NY now owns 42,220 shares of the company’s stock worth $264,000 after buying an additional 4,287 shares during the period. Institutional investors and hedge funds own 21.26% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2017/12/26/rockwell-medical-rmti-downgraded-to-sell-at-bidaskclub.html.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.